Ullenhag G J, Spendlove I, Watson N F S, Kallmeyer C, Pritchard-Jones K, Durrant L G
Academic Department of Clinical Oncology, Nottingham City Hospital, Nottingham, NG5 1PB, UK.
Clin Immunol. 2008 Aug;128(2):148-54. doi: 10.1016/j.clim.2008.03.512. Epub 2008 May 27.
We assessed T-cell responses in young osteosarcoma patients vaccinated with 105AD7, 1-6 months after having received chemotherapy. 105AD7 is a human anti-idiotypic antibody mimicking CD55, a glycoprotein that protects from attack by complement and which is overexpressed on osteosarcoma cells. Seven out of 21 investigated patients made a IFN-gamma T-cell response against the vaccine, 105AD7 as assessed by ELISPOT. Cytokine secretion was analysed using Luminex assays and revealed TNF-alpha and GM-CSF responses not only to the vaccine but also towards the native antigen, CD55, in 5 / 14 (36%) of investigated patients. Importantly, the Luminex assay was found to be more sensitive than the more established T-cell assays (ELISPOT and proliferation assay), since responses towards the native antigen were recorded in this assay. Clinical responses and induction of immune responses to both the anti-idiotype and the native CD55 antigen support the use of CD55 as a target in cancer treatment.
我们评估了在接受化疗1至6个月后接种105AD7疫苗的年轻骨肉瘤患者的T细胞反应。105AD7是一种模拟CD55的人抗独特型抗体，CD55是一种糖蛋白，可保护细胞免受补体攻击，且在骨肉瘤细胞上过度表达。通过ELISPOT检测，在21名接受调查的患者中，有7名对疫苗105AD7产生了IFN-γ T细胞反应。使用Luminex检测法分析细胞因子分泌情况，结果显示，在14名接受调查的患者中有5名（36%）不仅对疫苗，而且对天然抗原CD55产生了TNF-α和GM-CSF反应。重要的是，发现Luminex检测法比更成熟的T细胞检测法（ELISPOT和增殖检测法）更敏感，因为该检测法记录了对天然抗原的反应。临床反应以及对抗独特型和天然CD55抗原的免疫反应诱导，支持将CD55用作癌症治疗的靶点。
